Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

2017548 citationsJournal Article

Authors

Good health and well-being

Published in: The Lancet

Volume 390, Issue 10091, pp. 276-288

Field-Weighted Citation Impact: 27.32